Bayer Signs $875 Million Deal to Buy Women’s Health Biotech
5 years ago 1 min read
Bayer AG struck an $875 million deal to acquire British women’s health biotech Kandy Therapeutics Ltd., bolstering its pharmaceuticals division before patents expire on some key products.
More Stories
Record Korean Cases; Trader’s Guide to Rollout: Virus Update
California Hits Record; Trader’s Guide to Rollout: Virus Update
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push